Veravas launched in 2017 with a mission that went far beyond just selling technology or building products. We want to impact healthcare, raising the bar for diagnostic accuracy, efficacy, and the scope of what can be tested. Below are some milestones and inflection points in this journey.
Veravas has launched their portfolio of products to improve the accuracy of current diagnostic test results by detecting and managing biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin. The new VeraBind Biotin will also support diagnostic manufacturers in redeveloping lab assays to be biotin-interference-free.
Alex Wittenberg at the Minneapolis/St. Paul Business Journal published a profile of Veravas, highlighting both its long-term potential in the billion-dollar IVD market and the upcoming launch of its first suite of products.
Register to receive updates and more information as it becomes available – from product launches to conference posters to novel partnerships and events.